TL/DR –
Coccidioidomycosis, an infectious disease caused by fungi, remains often undiagnosed leading to an increase in its cases, especially in the US states of Arizona and California. This delay in diagnosis is due to the resemblance of its symptoms to other respiratory diseases, thus leading to patients getting multiple rounds of antibiotics before getting correctly diagnosed. A study using health insurance claims data identified risk factors for these delays as patients aged over 65 years, living in rural areas and having a history of lung diseases, with the delay in diagnosis resulting in an unnecessary prescription of antibiotics.
Understanding and Addressing Diagnostic Delays in Coccidioidomycosis
Coccidioidomycosis, an infectious disease, is caused by fungi from the Coccidioides genus, with C. immitis and C. posadasii being the leading culprits. Predominantly reported in Arizona and California, the geographic range of this infection seems to be expanding within the United States, with an increasing incidence (source). Infections are usually contracted through the inhalation of airborne arthroconidia, the fungal spores, resulting in symptoms resembling viral respiratory infections or pneumonia.
Challenges in Diagnosing Coccidioidomycosis
Diagnosing coccidioidomycosis can be difficult due to its nonspecific symptoms and overlaps with bacterial pneumonia or other respiratory conditions. Many patients are often subjected to multiple courses of antibiotics before a correct diagnosis is made (source). The consequences of delayed diagnosis, such as obscured infection timelines, can impair public health response and disease surveillance efforts.
The Need for Improved Diagnostic Practices
Considering the potential diagnostic delays for coccidioidomycosis, there is an urgent need to improve the identification of the incidence and factors associated with such delays. The objective of this study was to explore the incidence of diagnostic delays, the average length of these delays, and the potential factors impacting delayed diagnosis using a large database of commercial insurance claims.
Study Methodology
This study was conducted retrospectively using the Merative MarketScan Research Databases, which contain one of the largest recorded databases of commercial insurance claims in the U.S (source). Patients with coccidioidomycosis were identified using specific International Classification of Diseases codes, and the study population was divided into different categories based on their healthcare visits before the index diagnosis (source).
Study Findings
The study found that roughly 60% of patients experienced at least one missed diagnostic opportunity, with the average diagnostic delay estimated at around 30 days. Older patients, those living in rural areas, and patients with underlying respiratory conditions were more likely to experience a delay in diagnosis. Additionally, a large number of missed diagnostic opportunities were found to occur in outpatient settings, suggesting the need for improved diagnostic testing access in these places.
Implications for Healthcare Practices
The study findings emphasize the need for improved clinician awareness and expanded access to timely diagnostic testing, particularly in outpatient settings. It also suggests considering alternative diagnoses, including endemic mycoses, for patients not improving on an initial course of antibiotics (source). Raising awareness and improving diagnostic practices are crucial steps toward enhancing outcomes for patients with coccidioidomycosis.
Limitations and Future Directions
Limited access to laboratory results or radiology reports to confirm cases of disease and the absence of clinical notes capturing pre-diagnosis symptoms are some limitations of this study. The study population was also restricted to commercially insured individuals, limiting the findings’ general applicability to uninsured populations or individuals with frequent gaps in insurance coverage.
—
Read More Health & Wellness News ; US News